First Citizens Bank & Trust Co. Has $8.07 Million Stock Holdings in AbbVie Inc. $ABBV

First Citizens Bank & Trust Co. trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 6.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,834 shares of the company’s stock after selling 2,433 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in AbbVie were worth $8,065,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in ABBV. CIBC Asset Management Inc lifted its holdings in AbbVie by 0.8% during the third quarter. CIBC Asset Management Inc now owns 320,907 shares of the company’s stock worth $74,299,000 after acquiring an additional 2,466 shares in the last quarter. TFR Capital LLC. increased its holdings in shares of AbbVie by 5.3% in the third quarter. TFR Capital LLC. now owns 16,399 shares of the company’s stock worth $3,797,000 after acquiring an additional 825 shares in the last quarter. BLB&B Advisors LLC raised its position in shares of AbbVie by 0.3% during the third quarter. BLB&B Advisors LLC now owns 87,556 shares of the company’s stock worth $20,273,000 after purchasing an additional 269 shares during the period. Sagespring Wealth Partners LLC lifted its holdings in shares of AbbVie by 12.4% during the 3rd quarter. Sagespring Wealth Partners LLC now owns 38,051 shares of the company’s stock valued at $8,810,000 after purchasing an additional 4,192 shares in the last quarter. Finally, Mendel Capital Management LLC grew its position in shares of AbbVie by 1.5% in the 3rd quarter. Mendel Capital Management LLC now owns 7,746 shares of the company’s stock valued at $1,794,000 after purchasing an additional 115 shares during the period. Institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

ABBV has been the topic of several research analyst reports. Morgan Stanley raised their target price on shares of AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research report on Tuesday. Guggenheim boosted their price objective on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research report on Monday, October 20th. Citigroup reduced their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research note on Monday, November 3rd. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $258.00 price target on shares of AbbVie in a research note on Thursday, January 15th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $248.11.

AbbVie Trading Up 0.5%

AbbVie stock opened at $219.21 on Friday. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The company has a fifty day simple moving average of $225.60 and a 200 day simple moving average of $217.41. The company has a market cap of $387.42 billion, a P/E ratio of 166.07, a price-to-earnings-growth ratio of 0.90 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the firm posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.2%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is currently 524.24%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.